Article

NEI awards grant to Cole Eye, Arteriocyte

The National Eye Institute (NEI) of the National Institutes of Health (NIH) has awarded a $310,000 grant to Arteriocyte and the Cleveland Clinic's Cole Eye Institute.

Cleveland-The National Eye Institute (NEI) of the National Institutes of Health (NIH) has awarded a $310,000 grant to Arteriocyte and the Cleveland Clinic's Cole Eye Institute.

As a part of its small business technology transfer program, Arteriocyte will use the grant to evaluate its cellular therapy product (ACY001) as a potential treatment for diabetic retinopathy.

Treatment for hypoxia, one of the main causes of diabetic retinopathy, is the aim of researchers.

Diabetic retinopathy is the leading cause of blindness among 8 million patients in the United States alone, according to the American Academy of Ophthalmology.

"We are thrilled to have the NIH's support in Arteriocyte's efforts to translate our cellular therapies further into disease categories with significant unmet medical need. The NEI's vote of confidence provides validation for our cellular therapy research and stresses the importance of continuing to develop this potential therapy," said Don Brown, Arteriocyte chief executive officer. "The grant provides an opportunity to understand better the effects on treating retinal neovascular disease with a cellular therapy designed to improve blood flow."

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
(Image credit: Ophthalmology Times) From MIGS to gene therapy: Inder Paul Singh, MD, celebrates the past and future of glaucoma care
(Image credit: Ophthalmology Times) NeuroOp Guru: Using OCT to forecast outcomes in ethambutol optic neuropathy
(Image credit: Ophthalmology Times) Inside NYEE’s new refractive solutions center with Kira Manusis, MD
(Image credit: Ophthalmology Times) Dilsher Dhoot, MD, on the evolution of geographic atrophy therapy: where are we now?
(Image credit: Ophthalmology Times Europe) Anat Loewenstein, MD, shares insights on the real-world results of remote retinal imaging
(Image credit: Ophthalmology Times) Two-wavelength autofluorescence for macular xanthophyll carotenoids with Christine Curcio, PhD
(Image credit: Ophthalmology Times) FLIO and the brain: Making the invisible visible with Robert Sergott, MD
(Image credit: Ophthalmology Times) Structure-function correlates using high-res OCT images with Karl Csaky, MD, PhD
(Image credit: Ophthalmology Times) SriniVas Sadda, MD, on high-res OCT of atrophic and precursor lesions in AMD
© 2025 MJH Life Sciences

All rights reserved.